Announcements

Updates on campus events, policies, construction and more.

close  

Information for Our Community

Whether you are part of our community or are interested in joining us, we welcome you to WashU Medicine.

close  


Visit the News Hub

40-year mystery solved: Common gut virus infects bacteria, not human cells

Study redefines picobirnaviruses as only the third known group of bacteria-infecting RNA viruses

by Marta Wegorzewska•October 29, 2026

Illustration of microbes in intestinesSara Moser/WashU Medicine

In Brief

  • Researchers found that picobirnaviruses infect bacteria within the human gut microbiome.
  • Only two other groups of RNA viruses are known to infect bacteria.
  • The findings open new opportunities to study how these viruses impact human health.

Thriving alongside trillions of bacteria in the human digestive tract is a vast population of viruses. Ever since one such denizen of the gut microbiome, known as picobirnavirus, was first spotted decades ago, researchers thought it directly infected human tissue and played a role in gastrointestinal illness. But researchers at Washington University School of Medicine in St. Louis and collaborators have just rewritten that story: This widespread virus infects gut bacteria, not human cells.

The findings, published Oct. 29 in Nature Microbiology, are a major milestone for the field of virology and redefine picobirnaviruses as only the third known family of bacteria-infecting RNA viruses ever discovered.

“This discovery changes our understanding of the gut ecosystem,” said David Wang, PhD, the Robert C. Packman Professor at WashU Medicine. “RNA viruses that infect bacteria in the human body were thought to be rare. But picobirnaviruses are abundant in the gut and knowing that they infect bacteria is a first step in enabling us to better understand what role they play in causing disease.”

Stomach bug or bacteria hunter?

For nearly four decades, scientists thought they had identified another human stomach bug.

Picobirnaviruses were first described in stool samples from patients suffering from diarrhea, turning up alongside notorious culprits such as rotavirus and norovirus. Without the tools to grow the virus in the laboratory, the researchers assumed the newcomer was directly attacking human cells to cause gastrointestinal misery.

That is, until advances in sequencing technology led the Wang lab to unexpectedly find traces of picobirnavirus genetic material while studying Caenorhabditis elegans, a microscopic roundworm often used in genetics research. Although humans and worms differ in many ways, one commonality is bacteria: Worms eat them, and humans carry trillions of them in their gut.

The researchers asked: Do picobirnaviruses infect bacteria?

First author Tianyu Gan, PhD, a postdoctoral research fellow in Wang’s lab, in collaboration with researchers at Cambridge University Hospitals NHS Foundation Trust, Flinders University and San Diego State University, set out to find the virus inside a bacterial host. He introduced human stool samples to microbe-free mice, establishing the first laboratory model where the virus could actively multiply. Next, Gan and team harvested the viral population from the mouse gut and grew it in lab dishes filled with gut bacteria under oxygen-free conditions. Because mammalian cells cannot survive without oxygen, the virus’ growth over 20 days suggested it was multiplying inside bacteria. Antibiotics that killed off the bacteria also halted the virus from multiplying.

Using advanced molecular imaging and cellular sorting, the researchers found picobirnaviruses inside a newly identified gut bacteria they named Candidatus Anaerotignum faecalis.

The presence of picobirnaviruses in the gut has been linked to clinical conditions including acute diarrhea, graft-versus-host disease (a complication of stem cell transplants) and Type 1 diabetes.

It’s possible that, although picobirnavirus doesn’t infect human cells directly, it could be destroying beneficial gut bacteria. Wiping out friendly microbes disrupts the gut ecosystem, allowing harmful pathogens to bloom and prompting bacteria to release toxins. Moreover, human gut cells can absorb viral particles and spark inflammation, without the virus multiplying inside human tissue.

On the other hand, detecting high levels of picobirnavirus in patients with these conditions does not prove the virus causes disease, Wang warned. Even if it not a pathogen, it could serve as a biomarker, signaling gut distress.

“The first step to understanding how a virus impacts human health is understanding what it infects,” Wang said. “Knowing that picobirnaviruses infect bacteria shifts our focus to the microbiome. It opens new opportunities to study how these viruses shape bacterial communities in the gut and how we might harness them for targeted therapies.”

 

Gan T, Rosen AL, Wang L, Vernon S, Droit L, Pinski AN, Wu G, Chica Cardenas LA, Mihindukulasuriya KA, Paredes A, Pios Z, Baldridge MT, Rimmer JE, Parkes M, Dinsdale EA, Edwards RA, Segall AM, Handley SA, Kau AL, Wang D. A human gut-associated picobirnavirus establishes the Picobirnaviridae as the third clade of RNA bacteriophages. October 29, 2026. Nature Microbiology. DOI: 10.1038/s41564-026-02523-z.

This research was supported by the National Institute for Health and Care Research Biomedical Research Centre: Cambridge, grant number NIHR203312; the Stephen I. Morse Fellowship; and the National Institutes of Health (NIH), grant numbers R01AI165915, RC2DK116713 and R01AI193051. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

About WashU Medicine

WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with 3,100 faculty. Its National Institutes of Health (NIH) research funding portfolio is the second largest among U.S. medical schools and has grown 78% since 2016. Together with institutional investment, WashU Medicine commits over $1.6 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently among the top five in the country, with more than 2,550 faculty physicians practicing at 200 locations. WashU Medicine physicians exclusively staff Barnes-Jewish and St. Louis Children’s hospitals — the academic hospitals of BJC HealthCare — and Siteman Cancer Center, a partnership between BJC HealthCare and WashU Medicine and the only National Cancer Institute-designated comprehensive cancer center in Missouri and southern Illinois. WashU Medicine physicians also treat patients at BJC’s community hospitals in our region. With a storied history in MD/PhD training, WashU Medicine recently dedicated $100 million to scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in every medical subspecialty as well as physical therapy, occupational therapy, and audiology and communications sciences.

Marta covers pathology & immunology, pediatrics, obstetrics & gynecology, anesthesiology, ophthalmology and technology management, among other topics. She holds a bachelor’s degree in biology from Georgetown University and a PhD in immunology from the University of California, San Francisco. She did her postdoctoral work in Washington University’s Department of Pathology & Immunology. Marta joined WashU Medicine Marketing & Communications in 2023 after working as a science writer in the Department of Biology on the Danforth Campus for five years.